Mileutis News
8 articles
Yotvata Dairy Farm Invests in Mileutis to Improve Milk Quality
Mileutis, an Israeli biopharmaceutical company, has announced a significant investment and expanded collaboration with Yotvata Dairy. This partnership aims to redefine the dairy industry by implementing a cutting-edge management system that reduces antibiotic use, enhances milk quality, and boosts sustainability. Yotvata Dairy Farm will invest millions of New Israeli Shekels in Mileutis, supporting the use of Imilac™ therapy to replace antibiotics in dairy farms. The collaboration follows successful clinical trials demonstrating Imilac™s effectiveness in improving milk yield and quality while reducing greenhouse gas emissions. This initiative aligns with the broader industry goal of achieving carbon neutrality by 2050. The partnership is expected to generate significant revenue and represents a major step towards more sustainable dairy farming practices.
PartnersInvestment
Israeli Startup Mileutis Finds Antibiotic Replacement for Dairy Industry
Israel's Mileutis trial shows better milk quality without antibiotics in cows
Mileutis’ Clinical Trial Achieves Dramatic Reduction in Antibiotic Use and Enhanced Milk Quality in Dairy Cows
Mileutis, an Israeli biopharmaceutical company, has successfully completed a clinical trial demonstrating the efficacy of its product, Imilac™, in replacing antibiotics in dairy cows during the dry-off period. The trial, conducted across seven dairy farms in Israel, showed that Imilac™ not only substitutes antibiotics but also enhances milk nutritional characteristics, increasing milk yield and improving cow welfare. The product has been patented and is seen as a breakthrough in sustainable dairy farming. Mileutis collaborates with major dairy providers like Yotvata Dairy and Tnuva, aligning with sustainability goals and reducing antibiotic use by up to 90%. This development is expected to positively impact the dairy industry, consumers, and the environment by promoting healthier milk production.
CustomersPartners
Antibiotic Alternative: Today Cows, Tomorrow Humans?
Mileutis, an Israeli bio-pharmaceutical company, has developed a natural alternative to antibiotics for dairy farming. The product, Imilac, uses peptides extracted from milk to boost cows immune systems, reducing the need for antibiotics. The company claims that Imilac is safer and more effective than antibiotics, and could be a game changer for the dairy industry. The product is close to receiving the necessary approvals for widespread use. Despite likely being more expensive than antibiotics, the company argues that it will benefit farmers as cows given Imilac yield more milk.
CustomersPartnersInvestment
Mileutis' Imilac™ product shown as a successful antibiotic alternative in the management of the leading problem of the dairy industry: Mastitis
Leading journal of dairy sciences recently publishes a study that presents a case for antibiotic alternatives to treat cows at dry-off
Mileutis, an Israeli biopharmaceutical company, has announced that a recent paper published in the Journal of Dairy Science supports the use of its Imilac bovine casein hydrolysate (bCNH) treatment as an alternative to antibiotics for managing Mastitis, a leading problem in the dairy industry. The study found that Imilac is an effective and safe alternative to antibiotics for Mastitis, reduction of Somatic Cell Counts (SCC), and milk enhancement in dairy cows. Mileutis is making significant strides towards combating anti-microbial resistance (AMR), often caused and exacerbated by the overuse of antibiotics.
Customers
Mileutis to Present at the 39th Annual J.P. Morgan Healthcare Conference
Israeli animal health co Mileutis raises $20m
Israeli animal health company Mileutis Ltd. has received a $20 million investment from US life sciences and healthcare investor NovaQuest Capital Management LLC. Mileutis is developing a product to help mitigate the use of antibiotics in animals, specifically addressing bovine mastitis in the dairy industry. The investment will support the continued development and commercialization of Mileutis novel therapies for animal health. Mileutis plans to introduce Imilac, a residue-free peptide, with estimated potential annual revenue of above $1 billion globally. The company aims to revolutionize the way veterinarians manage mastitis and reduce antibiotic use in animal health management.
Investment
